PE20050464A1 - Formulacion farmaceutica de la sal sodica del telmisartan - Google Patents
Formulacion farmaceutica de la sal sodica del telmisartanInfo
- Publication number
- PE20050464A1 PE20050464A1 PE2004000417A PE2004000417A PE20050464A1 PE 20050464 A1 PE20050464 A1 PE 20050464A1 PE 2004000417 A PE2004000417 A PE 2004000417A PE 2004000417 A PE2004000417 A PE 2004000417A PE 20050464 A1 PE20050464 A1 PE 20050464A1
- Authority
- PE
- Peru
- Prior art keywords
- sodium salt
- substances
- pharmaceutical formulation
- methyl
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE LA SAL SODICA CRISTALINA DE 4´-[[2-n-PROPIL-4-METIL-6-(1-METIL-BENCIMIDAZOL-2-IL)-BENCIMIDAZOL-1-ILMETIL]-BIFENIL-2-CARBOXILICO (TELMISARTAN), EN UNA CANTIDAD DE 60-90mg Y UN AGENTE DIURETICO 6-CLORO-3,4-DIHIDRO-2H-1,2,4-BENZOTIADIAZINA-7-SULFONAMIDA-1,1-DIOXIDO (HIDROCLOROTIAZIDA) EN UNA CANTIDAD DE 10-15mg o 20-30mg JUNTO CON SUSTANCIAS COADYUVANTES DE FORMULACION, SELECCIONADOS DE: MANITOL, SORBITOL, XILITA, SACAROSA, CARBONATO DE CALCIO, FOSFATO DE CALCIO, ESTEARATO DE MAGNESIO, HIDROXIPROPIL-CELULOSA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE ESTA COMPOSICION DONDE LAS SUSTANCIAS ACTIVAS Y LAS SUSTANCIAS COADYUVANTES SE PRESENTAN COMO UNA MASA COMPRIMIDA DE UN GRANULADO SECO PARA LA FORMACION DE TABLETAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10319450A DE10319450A1 (de) | 2003-04-30 | 2003-04-30 | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050464A1 true PE20050464A1 (es) | 2005-07-04 |
Family
ID=33305059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000417A PE20050464A1 (es) | 2003-04-30 | 2004-04-28 | Formulacion farmaceutica de la sal sodica del telmisartan |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1622612B9 (es) |
JP (2) | JP5156231B2 (es) |
KR (1) | KR20060008943A (es) |
CN (1) | CN100589802C (es) |
AR (2) | AR044142A1 (es) |
AT (1) | ATE388703T1 (es) |
AU (1) | AU2004233581B2 (es) |
BR (1) | BRPI0409809A (es) |
CA (1) | CA2524091C (es) |
CL (1) | CL2004000899A1 (es) |
DE (2) | DE10319450A1 (es) |
DK (1) | DK1622612T3 (es) |
ES (1) | ES2303634T4 (es) |
IL (1) | IL171465A (es) |
MX (1) | MXPA05011647A (es) |
NZ (1) | NZ543775A (es) |
PE (1) | PE20050464A1 (es) |
RU (1) | RU2372918C2 (es) |
TW (1) | TWI364278B (es) |
UY (1) | UY28293A1 (es) |
WO (1) | WO2004096215A1 (es) |
ZA (1) | ZA200507223B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
DE10319592A1 (de) * | 2003-05-02 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern |
US7943781B2 (en) | 2004-10-18 | 2011-05-17 | Dr. Reddy's Laboratories Limited | Process for preparing telmisartan |
US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
WO2007144175A2 (en) | 2006-06-16 | 2007-12-21 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
WO2009058950A2 (en) * | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
CZ2008740A3 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
PL2443094T3 (pl) | 2009-06-19 | 2013-08-30 | Krka Tovarna Zdravil D D Novo Mesto | Sposób wytwarzania telmisartanu |
EP2448575A2 (en) * | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
JP2011136908A (ja) * | 2009-12-25 | 2011-07-14 | Kyowa Yakuhin Kogyo Kk | アンギオテンシンii受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンii受容体拮抗剤の保存安定性向上方法 |
CA2706292A1 (en) * | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
KR102117282B1 (ko) * | 2010-11-15 | 2020-06-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈관보호성 및 심장보호성 항당뇨 치료요법 |
AU2012303683B2 (en) * | 2011-08-26 | 2016-09-08 | Wockhardt Limited | Methods for treating cardiovascular disorders |
CN102526037B (zh) * | 2012-02-10 | 2014-08-27 | 重庆康刻尔制药有限公司 | 一种替米沙坦药物组合、片剂及其制备方法 |
EP2649996A1 (en) * | 2012-04-11 | 2013-10-16 | Laboratorios Del. Dr. Esteve, S.A. | Crystalline forms of sartans like telmisartan with beta blockers |
JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
JP6428340B2 (ja) * | 2014-05-23 | 2018-11-28 | ニプロ株式会社 | テルミサルタンを含む医薬組成物の造粒方法 |
JP5956034B1 (ja) * | 2015-07-27 | 2016-07-20 | エルメッド エーザイ株式会社 | テルミサルタン含有医薬組成物 |
CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
JP4107831B2 (ja) * | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | 医薬組成物 |
BR0213487A (pt) * | 2001-10-26 | 2004-11-03 | Ciba Sc Holding Ag | Produção de cetoácidos |
DE10153737A1 (de) * | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
DK1854454T3 (da) * | 2002-01-16 | 2014-01-13 | Boehringer Ingelheim Pharma | Fremgangsmåde til fremstilling af amorf telmisartan |
DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
-
2003
- 2003-04-30 DE DE10319450A patent/DE10319450A1/de not_active Withdrawn
-
2004
- 2004-04-27 DE DE502004006500T patent/DE502004006500D1/de not_active Expired - Lifetime
- 2004-04-27 WO PCT/EP2004/004425 patent/WO2004096215A1/de active IP Right Grant
- 2004-04-27 AU AU2004233581A patent/AU2004233581B2/en not_active Ceased
- 2004-04-27 BR BRPI0409809-9A patent/BRPI0409809A/pt not_active Application Discontinuation
- 2004-04-27 EP EP04729635A patent/EP1622612B9/de not_active Expired - Lifetime
- 2004-04-27 CA CA2524091A patent/CA2524091C/en not_active Expired - Fee Related
- 2004-04-27 AT AT04729635T patent/ATE388703T1/de active
- 2004-04-27 CN CN200480011725A patent/CN100589802C/zh not_active Expired - Fee Related
- 2004-04-27 JP JP2006500100A patent/JP5156231B2/ja not_active Expired - Fee Related
- 2004-04-27 MX MXPA05011647A patent/MXPA05011647A/es active IP Right Grant
- 2004-04-27 ES ES04729635T patent/ES2303634T4/es not_active Expired - Lifetime
- 2004-04-27 RU RU2005137031/15A patent/RU2372918C2/ru not_active IP Right Cessation
- 2004-04-27 KR KR1020057020575A patent/KR20060008943A/ko active Search and Examination
- 2004-04-27 NZ NZ543775A patent/NZ543775A/en not_active IP Right Cessation
- 2004-04-27 DK DK04729635T patent/DK1622612T3/da active
- 2004-04-28 UY UY28293A patent/UY28293A1/es not_active Application Discontinuation
- 2004-04-28 PE PE2004000417A patent/PE20050464A1/es not_active Application Discontinuation
- 2004-04-28 CL CL200400899A patent/CL2004000899A1/es unknown
- 2004-04-29 TW TW093112090A patent/TWI364278B/zh not_active IP Right Cessation
- 2004-04-30 AR ARP040101480A patent/AR044142A1/es active Pending
-
2005
- 2005-09-08 ZA ZA200507223A patent/ZA200507223B/en unknown
- 2005-10-19 IL IL171465A patent/IL171465A/en not_active IP Right Cessation
-
2010
- 2010-03-16 JP JP2010059404A patent/JP5254268B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-17 AR ARP120102583A patent/AR087210A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050464A1 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
CO5130023A1 (es) | Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico | |
ES2079743T3 (es) | Tableta para chupar o masticar. | |
PE20001058A1 (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial | |
BRPI0412489A (pt) | composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima | |
BRPI0709847B8 (pt) | composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio | |
PE20040439A1 (es) | Combinacion de compuestos organicos | |
PE20061017A1 (es) | Formulacion farmaceutica mediante compresion directa de un inhibidor de dipeptidil-peptidasa iv y proceso | |
ES2187822T3 (es) | Comprimidos de disgregacion rapida. | |
GT200900154A (es) | Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
AR021595A1 (es) | Composiciones y metodos para tratar cabello y piel utilizando sistemas de suministro acuoso. | |
MX2009003030A (es) | Forma galenita para la administracion por via transmucosa de principios activos. | |
HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
PE66998A1 (es) | Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2 | |
WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
AR065073A2 (es) | Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo | |
ES2195638T3 (es) | Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida. | |
AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
PE20061245A1 (es) | Composiciones para la transmision transmucosa oral de la metformina | |
PE20030323A1 (es) | Composicion farmaceutica | |
CO5640085A2 (es) | Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato | |
ATE291421T1 (de) | Pharmazeutische, ramipril enthaltende brauseformulierung | |
PE20050414A1 (es) | Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico | |
BRPI0408805A (pt) | composição farmacêutica contendo complexo de platina e método de fabricação da mesma | |
ES2059260B1 (es) | Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |